HIGHLIGHTS
- who: Rachel Evans from the Clu00ednica Mi Tres Torres, Spain University of Sassari, Italy have published the research: Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC, in the Journal: (JOURNAL)
- what: The authors report the results of a phase I clinical trial investigating the combination of CIMAvax-EGF with nivolumab as secondline therapy in metastatic NSCLC. The aim of the phase I study is to determine the safety profile and to establish a recommended phase II dose of CIMAvax . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.